Improving the effectiveness of natural killer cells for cancer treatment
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
['FUNDING_SBIR_2'] · KYTOPEN CORP · NIH-11036417
This study is looking at a new way to boost the power of your immune cells, called natural killer cells, to better fight acute myeloid leukemia (AML), using a special technique to make them stronger against cancer, which could lead to better treatment options for patients like you.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | KYTOPEN CORP (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11036417 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the ability of natural killer (NK) cells, a type of immune cell, to fight cancer, specifically acute myeloid leukemia (AML). The team is using a novel method called Flowfect™ to genetically modify NK cells, making them more effective at targeting and destroying cancer cells. The research involves two phases: the first phase aims to optimize the genetic modification process, while the second phase will explore how these modified cells can be used in pre-clinical settings. Patients may benefit from this innovative approach to immunotherapy, which seeks to improve the outcomes of existing cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking advanced treatment options.
Not a fit: Patients with other types of cancers or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in using genetic modification techniques for enhancing NK cell function, indicating potential for success in this novel approach.
Where this research is happening
CAMBRIDGE, UNITED STATES
- KYTOPEN CORP — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHIU, MICHAEL — KYTOPEN CORP
- Study coordinator: CHIU, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases